4 February 2025
Roquefort Therapeutics
plc
("Roquefort Therapeutics" or the "Company")
Director/PDMR
Shareholding
Roquefort Therapeutics (LSE:ROQ),
the Main Market listed biotech company focused on
developing first in class medicines in the high
value and high growth immunology and oncology
markets, advises that Stephen West,
Executive Chairman and Ajan Reginald, CEO have purchased ordinary
shares of £0.01 each in the Company ("Ordinary Shares"), as
detailed below:
|
Director
|
Number of Ordinary Shares
Acquired
|
Average Price Paid per
Share
|
Total Consideration
Paid
|
Number of Ordinary Shares Now
Held
|
% of Company's Issued
Capital
|
|
Stephen West*
|
400,000
|
2.57
pence
|
£10,338.85
|
6,710,853
|
4.9%
|
|
Ajan Reginald
|
191,059
|
2.60
pence
|
£5,000.00
|
12,537,472
|
9.2%
|
*4,628,485 of Mr West's Ordinary
Shares are held in the name of Cresthaven Investments Pty Ltd ATF
the Bellini Trust.
-ENDS-
Enquiries:
|
Roquefort Therapeutics plc
|
+44 (0)20
3918 8633
|
|
Stephen West (Chairman) / Ajan
Reginald (CEO)
|
|
|
SP
Angel Corporate Finance LLP (Broker)
David Hignell / Vadim Alexandre /
Devik Mehta
|
+44 (0) 20
3470 0470
|
|
Burson Buchanan (Public Relations)
Ben Romney / Jamie Hooper / George
Beale
|
+44 (0)20
7466 5000
|
|
Peak
IR (Investor Relations)
Seb Wykeham
|
+33 (0)7
44 44 15 42
|
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ) is
a Main Market listed biotech company developing first in class
drugs in the high value and high growth immunology and oncology markets prior
to partnering with big pharma.
Roquefort Therapeutics' portfolio
consists of five novel patent-protected pre-clinical anti-cancer
medicines. The highly complementary profile of five
best-in-class medicines consists of:
·
Midkine antibodies with
significant in
vivo efficacy and toxicology studies;
·
Midkine RNA therapeutics with novel anti-cancer
gene editing action;
·
Midkine mRNA therapeutics with novel anti-cancer
approach;
·
STAT-6 siRNA therapeutics targeting solid tumours
with significant in
vivo efficacy; and
·
MK cell therapy with direct and NK cell-mediated
anti-cancer action
For further information on Roquefort
Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on
Twitter.
This announcement contains inside information for the purposes
of Article 7 of the UK version of Market Regulation (EU) No
596/2014 on Market Abuse as it forms part of UK domestic law by
virtue of the European Union (Withdrawal) Act 2018, as amended ("UK
MAR").
The
notification below, made in accordance with the requirements of the
UK MAR, provides further detail:
NOTIFICATION AND PUBLIC DISCLOSURE
OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES
AND PERSONS CLOSELY ASSOCIATED WITH THEM
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Stephen West
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Executive Chairman
|
|
b)
|
Initial notification
/Amendment
|
Initial
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Roquefort Therapeutics
plc
|
|
b)
|
LEI
|
254900P4SISIWOR9RH34
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary shares of £0.01 par
value
ISIN: GB00BMDQ2T15
|
|
b)
|
Nature of the transaction
|
Purchase of 400,000 ordinary
shares
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
|
2.57 pence per share
|
400,000
|
|
d
|
Aggregated information
- Aggregated volume
- Price
|
- 400,000
- 2.57p
|
|
e)
|
Date of the transactions
|
4 February 2025
|
|
f)
|
Place of the transactions
|
London Stock Exchange (XLON); Main
Market
|
The
notification below, made in accordance with the requirements of the
UK MAR, provides further detail:
NOTIFICATION AND PUBLIC DISCLOSURE
OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES
AND PERSONS CLOSELY ASSOCIATED WITH THEM
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Ajan Reginald
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Executive Officer
|
|
b)
|
Initial notification
/Amendment
|
Initial
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Roquefort Therapeutics
plc
|
|
b)
|
LEI
|
254900P4SISIWOR9RH34
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary shares of £0.01 par
value
ISIN: GB00BMDQ2T15
|
|
b)
|
Nature of the transaction
|
Trust distribution of 34,432
ordinary shares
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
|
2.6 pence per share
|
191,059
|
|
d
|
Aggregated information
- Aggregated volume
- Price
|
- 191,059
- 2.6p
|
|
e)
|
Date of the transactions
|
4 February 2025
|
|
f)
|
Place of the transactions
|
London Stock Exchange (XLON); Main
Market
|
